Georges Bismuth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Georges Bismuth has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Didier Bouscary
Universite Paris Cite, INSERM, CNRS, Institut Cochin, Paris - France ; Hematology care unit and laboratory, AP-HP, Hopital Cochin, Paris - France
25 shared publications - Fathia Mami-Chouaib
INSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine-University Paris-Sud, Université Paris-Saclay, 94805 Villejuif, France
25 shared publications - Jacques Dutrieux
Université Paris Cité, CNRS, INSERM, Institut Cochin, F-75014 Paris, France
25 shared publications - Justine Decroocq
Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie clinique, Hôpital Cochin, Paris, France
25 shared publications - Luca Simula
Univ. Paris-Cité, INSERM, CNRS, Institut Cochin, Paris, France
25 shared publications - Marianne Mangeney
Unité des Rétrovirus Endogènes et Eléments Rétroïdes des Eucaryotes Supérieurs, CNRS UMR 8122, Institut Gustave Roussy, Villejuif, France
25 shared publications
Latest Publications
- Open Access
- 11 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors
AS1842856 treatment does not allow T cells proliferation.
- 11 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors
AS1842856 treatment does not allow T cells proliferation.
- Open Access
- 11 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors
AS1842856 promotes Tfh polarization.
- 11 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors
AS1842856 promotes Tfh polarization.
- Open Access
- 11 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors
CAR-TAS cells are more potent in vivo.
- 11 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors
CAR-TAS cells are more potent in vivo.
- Open Access
- 11 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors
Main characteristics of patients.
- 11 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors
Main characteristics of patients.
- Open Access
- 11 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors
CAR expression in non-activated cells after culture in presence of cytokines.
- 11 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors
CAR expression in non-activated cells after culture in presence of cytokines.
- Open Access
- 11 June 2024
- Published by American Association for Cancer Research (AACR)
Data from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors
Chimeric antigen receptor (CAR) T cells have shown promising results in the treatment of B-cell malignancies. Despite the successes, challenges remain. One of them directly involves the CAR T-cell manufacturing process and especially the ex vivo activation phase. While this is required to allow infection and expansion, ex vivo activation dampens the antitumor potential of CAR T cells. Optimizing the nature of the T cells harboring the CAR is a strategy to address this obstacle and has the potential to improve CAR T-cell therapy, including for solid tumors. Here, we describe a protocol to create CAR T cells without ex vivo preactivation by inhibiting the transcription factor FOXO1 (CAR TAS cells). This approach made T cells directly permissive to lentiviral infection, allowing CAR expression, with enhanced antitumor functions. FOXO1 inhibition in primary T cells (TAS cells) correlated with acquisition of a stem cell memory phenotype, high levels of granzyme B, and increased production of TNFα. TAS cells displayed enhanced proliferative and cytotoxic capacities as well as improved migratory properties. In vivo experiments showed that CAR TAS cells were more efficient at controlling solid tumor growth than classical CAR T cells. The production of CAR TAS from patients’ cells confirmed the feasibility of the protocol in clinic.
- 11 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors
Chimeric antigen receptor (CAR) T cells have shown promising results in the treatment of B-cell malignancies. Despite the successes, challenges remain. One of them directly involves the CAR T-cell manufacturing process and especially the ex vivo activation phase. While this is required to allow infection and expansion, ex vivo activation dampens the antitumor potential of CAR T cells. Optimizing the nature of the T cells harboring the CAR is a strategy to address this obstacle and has the potential to improve CAR T-cell therapy, including for solid tumors. Here, we describe a protocol to create CAR T cells without ex vivo preactivation by inhibiting the transcription factor FOXO1 (CAR TAS cells). This approach made T cells directly permissive to lentiviral infection, allowing CAR expression, with enhanced antitumor functions. FOXO1 inhibition in primary T cells (TAS cells) correlated with acquisition of a stem cell memory phenotype, high levels of granzyme B, and increased production of TNFα. TAS cells displayed enhanced proliferative and cytotoxic capacities as well as improved migratory properties. In vivo experiments showed that CAR TAS cells were more efficient at controlling solid tumor growth than classical CAR T cells. The production of CAR TAS from patients’ cells confirmed the feasibility of the protocol in clinic.
- Open Access
- 11 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors
Schematic representation of lentiviral constructs.
- 11 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors
Schematic representation of lentiviral constructs.
- Open Access
- 11 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors
FOXO1 inhibition promotes T cells motility in A549 tumors.
- 11 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors
FOXO1 inhibition promotes T cells motility in A549 tumors.